Brief: Corbus Pharmaceuticals Reports Results From Phase 1A Study Of Oral CB1 Inverse Agonist CRB-913 For The Treatment For Obesity Demonstrating Favorable Safety Profile And Emerging Evidence Of Weight Loss

Corbus Pharmaceuticals Holdings

11/12/2025 12:47

Dec 11 (Reuters) - Corbus Pharmaceuticals Holdings Inc CRBP.O:

CORBUS PHARMACEUTICALS REPORTS RESULTS FROM PHASE 1A STUDY OF ORAL CB1 INVERSE AGONIST CRB-913 FOR THE TREATMENT FOR OBESITY DEMONSTRATING FAVORABLE SAFETY PROFILE AND EMERGING EVIDENCE OF WEIGHT LOSS

CORBUS PHARMACEUTICALS HOLDINGS INC - CRB-913 SAFE AND WELL-TOLERATED ACROSS ALL DOSES

CORBUS PHARMACEUTICALS HOLDINGS INC - PLACEBO-ADJUSTED WEIGHT LOSS OF 2.9% OBSERVED AT DAY 14

CORBUS PHARMACEUTICALS HOLDINGS INC - 12-WEEK DOSE-FINDING STUDY INITIATED, COMPLETION EXPECTED SUMMER 2026

Source text: ID:nGNX5qp4T0

Further company coverage: CRBP.O

 ((Reuters.Briefs@thomsonreuters.com;))